Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes

Inclusion Criteria: * Type 2 diabetes, including newly-diagnosed who have never received insulin or an insulin analogue before, at the discretion of the physician. Exclusion Criteria: * Currently treated with NovoMix® 30 * Subjects who are unlikely to comply with protocol requirements * Previously enrolled in this study * Hypersensitivity to biphasic insulin aspart or to any of the excipients * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months